From Pandemic Response to Pandemic Recovery - Opportunities for Viral Hepatitis Elimination - John Ward, MD

Conference on Liver Disease in Africa (COLDA) 2022

Call for Action - “Call for Action - “We Need Testing and Treatment - NOW” - Bisi Bright, B.Pharm(Hons), MPH, FPCPharm, FPSN, C.Psych

Conference on Liver Disease in Africa (COLDA) 2022

Call for Action - “We Need Solutions” - Agnes Binagwaho, MD, M(Ped), PhD

Conference on Liver Disease in Africa (COLDA) 2022

Call for Action - “We Need (HQ) Data - To Plan Services” - Olufunmilayo Lesi, MD, MBA, FMCP

Conference on Liver Disease in Africa (COLDA) 2022

Call for Action - “We Need to Address the Challenges - Now” - The South African Experience - Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD

Conference on Liver Disease in Africa (COLDA) 2022

International Viral Hepatitis Elimination Meeting (IVHEM) 2022 - Promo Video

International Viral Hepatitis Elimination Meeting (IVHEM) 2022

Community Perspective - Michael Meulbroek

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

DDIs Relevant for COVID-19 Therapeutic Agents & Implementation Challenges - Fiona Marra, MPharm, MSc

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Session 1 - Abstract Discussion

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Policy Perspective - Heather-Marie Schmidt

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

#4 A Phase 1 Drug-Drug Interaction Study to Investigate (...) - Myreen Tomas

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Current Situation of HIV and Monkeypox in Catalonia - Pep Coll, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Emerging Strategies for Treating and Preventing Monkeypox, Ruth Byrne, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Current COVID-19 Therapies and Variants - Stefano Bonora, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

#1Predicting Pharmacokinetics of Nirmatrelvir/Ritonavir in(...) - Erica Leertouwer

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

#3 - Pharmacokinetics of the small interfering RNA (siRNA) JNJ-73763989 (...) - Thomas Kakuda

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

#8 - Pharmacokinetics of First-line Tuberculosis Drugs in Pregnant (...) - Marije Van Schalkwyk

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Endogenous Biomarker Informed Approach to Assess Potential - Vikram Arya, PhD, FCP

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Social Innovations in Health, Especially with Implications for HIV and Other Co-Infections | Beatrice Halpaap, Pharm D, MPH

APACC 2022

New Development of Therapeutics for COVID Treatment | Steve McGloughlin, Bsc, BMed, FCICM, FRACP, MPH&TM, PGDipEcho

APACC 2022

New Antiretroviral Drugs/Formulations for the Treatment of PLWH and for Prevention of HIV | Jennifer Hoy, AM, FRACP, FAHMS

APACC 2022

Epidemiology of Hepatitis Delta in the Asian Region – Do We Need Screening & What Are the Treatment Options? | Chien-Ching Hung, MD, PhD

APACC 2022

Talaromycosis - A Leading Cause of Death in Patients with Advanced HIV Disease in Southern China | Hao Liang, M.D., Ph.D.

APACC 2022

Burden of Systemic Mycoses in Advanced HIV Disease in Vietnam | Vu Quoc Dat, MD, PhD

APACC 2022